Bioventus 第二季度财报电话会议要点
· finance.yahoo.com
Bioventus (NASDAQ:BVS) 报告 2026 年第二季度收入增长 4%，并重申了全年财务展望，理由是其疼痛治疗业务实现了两位数增长、持续减少债务，并加大了对富血小板血浆、外周神经刺激和超声产品的投资。
Adjusted earnings were $0.22 per diluted share, compared with $0.21 a year earlier. Chief Financial Officer Mark Singleton said adjusted net income rose to $20 ...